Companies: 10,795·Total market cap: $144.5T
Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGXNASDAQHealthcare● Active
$1.29
+$0.01(+0.78%)
Market Cap$48564449
P/E Ratio
52W High$3.95
52W Low$1.24
Overview

Metagenomi, Inc. Common Stock (MGX) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mgx · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Metagenomi, Inc. Common Stock (MGX) measures how much investors pay for each dollar of the company's trailing earnings. MGX's current PE ratio of N/A is calculated by dividing its stock price of $1.29 by its TTM earnings per share of -$2.29.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.57
Based on 2 analysts
EPS (TTM)
-$2.29
TTM · diluted EPS
PEG Ratio
0.06
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Metagenomi, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2021 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Metagenomi, Inc. Common Stock
Metagenomi, Inc. Common StockYou
MGX
$49MN/A-$2.29
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.
ADVM
$96MN/A-$6.62
ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc.
ALXO
$211MN/A-$1.90
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.
ARTV
$168MN/A-$3.43
aTyr Pharma, Inc.
aTyr Pharma, Inc.
ATYR
$43MN/A-$0.80
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited
CNTB
$139MN/A-$1.00
Precision BioSciences, Inc.
Precision BioSciences, Inc.
DTIL
$87MN/A-$3.63

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 5 of 5 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-2.36
2024-12-31
FY2024
$-2.09
2023-12-31
FY2023
$-1.82
2022-12-31
FY2022
$-1.16
2021-12-31
FY2021
$-3.62

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Metagenomi, Inc. Common Stock (MGX) measures how much investors pay for each dollar of the company's trailing earnings. MGX's current PE ratio of N/A is calculated by dividing its stock price of $1.29 by its TTM earnings per share of -$2.29.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.29 ÷ -$2.29 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MGX pe ratio · 6 questions

MGX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.29 and TTM EPS of -$2.29. Data sourced from Financial Modeling Prep via MGX's SEC 10-K and 10-Q filings.

MGX PE ratioWhat is MGX PE ratioCurrent PE ratio of MGXMGX PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Metagenomi, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09